top of page
![Boston_H_color[33632]_edited.png](https://static.wixstatic.com/media/e60c5c_0b72738a80554196840094a8e387c5ed~mv2.png/v1/fill/w_338,h_77,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Boston_H_color%5B33632%5D_edited.png)
Tue, Mar 19
|Mistral
The Only CDK4 & 6 Inhibitor Approved Across HR+, HER2- MBC
This program will present efficacy and safety data for Verzenio, a CDK4 & 6 inhibitor approved in combination with fulvestrant, in combination with an Al, and as a single agent for HR+, HER2- advanced or MBC.
Registration is Closed
See other events
Time & Location
Mar 19, 2019, 6:00 PM
Mistral, 223 Columbus Ave, Boston, MA 02116, USA
Guests
About The Event
Speaker
Yelena Novik, MD
Associate Professor Medical Oncology
NYU Langone
Program Description
This program will present efficacy and safety data for Verzenio, a CDK4 & 6 inhibitor approved in combination with fulvestrant, in combination with an Al, and as a single agent for HR+, HER2- advanced or MBC.
Program Objectives
- Discuss the unmet needs of women with HR+, HER2- MBC
- Examine the efficacy and safety profile of Verzenio
- Review practical consideration for the use of Verzenio
RSVP to Christina Roderick at Roderick_Christina@lilly.com or by phone at (508) 954-2450.
bottom of page